Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers - The State University of New Jersey, United States; Center for Dermal Research (CDR) & Laboratory for Drug Delivery (LDD) & NJ Center for Biomaterials, United States.
Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers - The State University of New Jersey, United States; Center for Dermal Research (CDR) & Laboratory for Drug Delivery (LDD) & NJ Center for Biomaterials, United States.
Int J Pharm. 2018 Jan 30;536(1):345-352. doi: 10.1016/j.ijpharm.2017.11.041. Epub 2017 Nov 21.
Dermal delivery of hydrophobic drugs by microemulsion (ME) formulations and effect from ME microstructures were studied. Anti-fungal drug, clotrimazole (CLOT), was used as the model compound. ME formulations possessing different microstructures were prepared using a ME system that contains isopropyl myristate as oil, Labrasol and Cremophor EL as surfactant and co-surfactant, and water. Permeation experiments on human cadaver skin were conducted for ME and the control formulations of different CLOT concentrations. Dermal delivery of CLOT assessed by the dermal tissue drug concentration was found to be significantly higher for MEs when compared with the control formulation, evidenced by dermal retention Enhancement Ratio (ER) of 5.1, 2.8, and 3.0 for tested O/W, bi-continuous, and W/O MEs, respectively. The highest concentration was observed with O/W ME, suggesting the ME microstructure is an important formulation variable for enhancing dermal delivery efficiency. ME gel formulations prepared by incorporating 1.0%(w/w) of Carbopol980 showed comparable dermal CLOT concentration to MEs, but up to 2.4 fold higher than the commercial CLOT cream product, Lotrimin. Furthermore, Fluorescein Isothiocynate (FITC), used as a model compound for highly hydrophobic drugs, was also studied for dermal delivery by MEs, and results show consistent ME microstructure effect, suggested by significantly higher FITC concentrations in all skin layers, SC, viable epidermis, and dermis, from O/W ME over bi-continuous and W/O MEs.
通过微乳液 (ME) 制剂和 ME 微结构的影响来研究疏水性药物的经皮传递。使用抗真菌药物克霉唑 (CLOT) 作为模型化合物。使用包含肉豆蔻酸异丙酯作为油、Labrasol 和 Cremophor EL 作为表面活性剂和助表面活性剂以及水的 ME 系统制备具有不同微观结构的 ME 制剂。对人体尸体皮肤进行 ME 和不同 CLOT 浓度的对照制剂的渗透实验。通过皮肤组织药物浓度评估 CLOT 的经皮传递,与对照制剂相比,ME 的 CLOT 传递明显更高,通过测试的 O/W、双连续和 W/O ME 的皮肤保留增强比 (ER) 分别为 5.1、2.8 和 3.0 证明了这一点。O/W ME 观察到最高浓度,表明 ME 微观结构是提高经皮传递效率的重要制剂变量。通过加入 1.0%(w/w)Carbopol980 制备的 ME 凝胶制剂显示出与 ME 相当的皮肤 CLOT 浓度,但比商业 CLOT 乳膏产品 Lotrimin 高 2.4 倍。此外,还研究了荧光素异硫氰酸酯 (FITC) 作为高度疏水性药物的模型化合物,通过 ME 进行经皮传递,结果表明 FITC 在所有皮肤层(SC、有活力的表皮和真皮)中的浓度均明显更高,这表明 O/W ME 比双连续和 W/O ME 的 ME 微结构效果更好。